文献速递中医内科中药与中成药合理使用

松龄血脉康胶囊治疗原发性高血压的系统评价与Meta分析

Efficacy and safety of Songling Xuemaikang capsule for essential hypertension: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Phytomedicine · 2022-09-20

该系统评价与Meta分析纳入34项随机对照试验共4306例患者,评估松龄血脉康胶囊(SXC)治疗原发性高血压的疗效与安全性。结果显示SXC联合降压药较单用降压药可额外降低诊室及24小时血压并改善高血压症状,单用SXC的24小时收缩压降幅弱于降压药,不良事件发生率组间无显著差异。

要点

  • SXC联合降压药可额外降低诊室收缩压约7.54 mmHg、舒张压约6.42 mmHg。
  • SXC联合降压药可额外降低24小时收缩压约6.88 mmHg、舒张压约4.31 mmHg。
  • SXC单用降24小时收缩压效果弱于降压药,联合用药安全性良好。

核心结论

  • SXC对原发性高血压有益,可降低血压、改善高血压症状且耐受性良好。

研究设计与样本

  • 系统评价与Meta分析,检索7个数据库,纳入34项随机对照试验共4306例患者。

主要发现

  • SXC联合降压药较单用降压药额外降低诊室收缩压(MD -7.54 mmHg,95%CI -8.92至-6.17,p<0.00001)和舒张压(MD -6.42 mmHg,95%CI -7.54至-5.29,p<0.00001)。
  • SXC联合降压药额外降低24小时收缩压(MD -6.88 mmHg,95%CI -8.36至-5.39,p<0.00001)和24小时舒张压(MD -4.31 mmHg,95%CI -6.55至-2.07,p=0.0002)。
  • SXC联合降压药改善高血压症状(SMD -1.09,95%CI -1.34至-0.84,p<0.00001)。
  • SXC单药降低24小时收缩压的效果劣于降压药(MD 2.07 mmHg,95%CI 0.19至3.96,p=0.03)。
  • SXC组与对照组不良事件发生率无显著差异。

临床怎么用

  • 对于原发性高血压患者,可考虑在降压药基础上联合SXC以进一步降低血压并改善症状。
  • 不宜推荐SXC单药替代降压药用于24小时收缩压控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension is one of the most significant public health challenges worldwide. An increasing number of patients prefer to incorporate traditional Chinese medicine into their hypertensive care. The Songling Xuemaikang capsule (SXC), a Chinese herbal formula, is widely used in China for essential hypertension. PURPOSE: To assess the efficacy and safety of SXC for essential hypertension. STUDY DESIGN: Systematic review and meta-analysis of randomized controlled trials (RCTs). METHODS: We conducted a systematic literature search of seven databases to identify randomized controlled trials of SXC for hypertension. The outcome measures included blood pressure parameters and patient-reported outcomes. Potential heterogeneity between the studies was resolved by subgroup and sensitivity analyses. The quality of the results was evaluated using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. RESULTS: A total of 34 trials with 4306 patients were included. The results showed that SXC plus antihypertensive drugs produced a greater effect on reducing systolic blood pressure (SBP) (MD: -7.54 mmHg; 95% CI: -8.92, -6.17; p < 0.00001), diastolic blood pressure (DBP) (MD: -6.42 mmHg; 95% CI: -7.54, -5.29; p < 0.00001), 24-hour SBP (MD: -6.88 mmHg; 95% CI: -8.36, -5.39; p < 0.00001), and 24-hour DBP (MD: -4.31 mmHg; 95% CI: -6.55, -2.07; p = 0.0002) and improving hypertensive symptoms (SMD: -1.09; 95% CI: -1.34, -0.84; p < 0.00001) than antihypertensive drugs alone. SXC monotherapy was less effective than antihypertensive drugs for 24-hour SBP reduction (MD: 2.07 mmHg; 95% CI: 0.19, 3.96; p = 0.03). No significant difference was observed in the incidence of adverse events between the SXC and control groups. CONCLUSION: SXC is beneficial for essential hypertension; it can lower BP, improve hypertensive symptoms and is well tolerated.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Meng T, Wang P, Xie X, et al. Efficacy and safety of Songling Xuemaikang capsule for essential hypertension: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2022. PMID: 36183476. doi:10.1016/j.phymed.2022.154459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。